AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Full Submission (WPAS) Dolutegravir/rilpivirine (Juluca®) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor

The meeting will now open to the public for the committee decisions

6. Chairman’s report (verbal update)

7. Appraisal 2: Limited Submission Brivaracetam (Briviact®) as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 to ≤ 15 years of age with epilepsy. Brivaracetam (Briviact®) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines

8. National Prescribing Indicators 2018-2019 : Analysis of Prescribing Data to June 2018

9. CEPP National Audit: Antipsychotics in Dementia

10. Medicines identified as Low Priority for funding in NHS Wales

11. Feedback from AWPAG meeting held 19th September 2018

Date of next meeting – Wednesday, 13th February 2019 in Cardiff